Gram-Positive Bacterial Infections Clinical Trial
Official title:
Model-informed Precision Dosing for Linezolid: a Pilot Randomized Clinical Trial
Study Rationale: Previous in vitro and retrospective in vivo studies suggest that optimal linezolid concentrations (between 2 and 7 mg/L) achieve clinical efficacy and microbiological eradication while minimizing side effects like thrombocytopenia and the emergence of resistance. No prospective or randomized clinical trial has confirmed these findings, and there is no consensus on how to adjust linezolid dosing to achieve optimal drug concentrations. Objectives: The primary objective is to determine if model-informed precision dosing optimizes linezolid dosing to achieve therapeutic trough concentrations compared to a standard dose. Secondary objectives include assessing the PK/PD profile, investigating the prevalence of linezolid resistance among gram-positive bacteria, assessing microbiological resolution of infection, and evaluating the safety and tolerability of linezolid. Methodology: This study is an open, monocentric pilot randomized controlled trial with two arms: standard dose therapy versus dose adjustment based on model-informed precision dosing using therapeutic drug monitoring and PK/PD targets developed in TMDx software. Sample Size: 28 patients, 14 in each group. Assumptions are based on only 25% of patients in intensive care achieving the optimal therapeutic range with standard dosing, compared to an expected 80% achieving this with model-informed precision dosing. Selection Criteria: Adult patients (18+ years) already starting linezolid treatment for gram-positive infections, expected to require treatment beyond the next calendar day. Exclusions include imminent death, expected or confirmed pregnancy, expected linezolid treatment of less than 4 days or more than 4 weeks. Outcomes: The primary endpoint is defined as the difference in the proportion of patients in the intervention and in the control groups who maintained a trough linezolid concentration of 2 to 7 mg/L on Day 7 and Day 13.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
| Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
| Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
| Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
| Completed |
NCT00079976 -
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
|
Phase 3 | |
| Terminated |
NCT00835783 -
Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation
|
N/A | |
| Completed |
NCT00081744 -
Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects
|
Phase 3 | |
| Completed |
NCT03747497 -
Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
|
Phase 2 | |
| Active, not recruiting |
NCT04911270 -
Clinical Decision Support Tool for Vancomycin Dosing in Children
|
N/A | |
| Completed |
NCT02750761 -
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
|
Phase 1 | |
| Completed |
NCT00406198 -
Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis
|
Phase 4 | |
| Completed |
NCT03560440 -
Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
|
||
| Completed |
NCT00147511 -
Time To Efficacy and Onset Of Action Of Linezolid
|
Phase 4 | |
| Terminated |
NCT00240747 -
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
|
Phase 3 | |
| Not yet recruiting |
NCT04917380 -
The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
|
||
| Completed |
NCT00736554 -
What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?
|
N/A | |
| Completed |
NCT03361163 -
Controlled Human Infection for Vaccination Against Streptococcus Pyogenes
|
Phase 1 | |
| Completed |
NCT00167960 -
Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
|
Phase 4 | |
| Completed |
NCT00874367 -
Early-Onset Sepsis Surveillance Study
|
N/A | |
| Completed |
NCT00167999 -
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
|
Phase 4 |